Soluble forms of RAGE in human diseases: Clinical and therapeutical implications

Current Medicinal Chemistry

Volumn 16, Issue 8, 2009, Pages 940-952

  Santilli, Francesca ^a   Vazzana, Natale ^a   Bucciarelli, Loredana G ^b   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Atherothrombosis; Biomarker; Diabetes mellitus; Endogenous secretory RAGE; Inflammation; Oxidative stress; Soluble RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ATORVASTATIN; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLICLAZIDE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; METHOTREXATE; PRAVASTATIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

AGING; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

DIABETES MELLITUS; DISEASE; HUMANS; MOLECULAR BIOLOGY; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; SOLUBILITY;

EID: 65649127808     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787581888     Document Type: Review

References (119)

1. Neeper, M.; Schmidt, A.M.; Brett, J.; Yan, S.D.; Wang, F.; Pan, Y.C.; Elliston, K.; Stern, D.; Shaw, A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem., 1992, 267, 14998-5004.
2. Schmidt, A.M.; Vianna, M.; Gerlach, M.; Brett, J.; Ryan, J.; Kao, J.; Esposito, C.; Hegarty, H.; Hurley, W.; Clauss, M.; Wang, F.; Pan, Y.C.; Tsang, T.C.; Stern, D. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem., 1992, 267, 14987-97.
3. Huebschmann, A.G.; Regensteiner, J.G.; Vlassara, H.; Reusch, J.E. Diabetes and advanced glycoxidation end products. Diabetes Care, 2006, 29, 1420-32.
4. Hofmann, M.A.; Drury, S.; Fu, C.; Qu, W.; Taguchi, A.; Lu, Y.; Avila, C.; Kambham, N.; Bierhaus, A.; Nawroth, P.; Neurath, M.F.; Slattery, T.; Beach, D.; McClary, J.; Nagashima, M.; Morser, J.; Stern, D.; Schmidt, A.M. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell, 1999, 97, 889-901.
5. Hori, O.; Brett, J.; Slattery, T.; Cao, R.; Zhang, J.; Chen, J.X.; Nagashima, M.; Lundh, E.R.; Vijay, S.; Nitecki, D.; Morser, J.; Stern, D.; Schmidt, A.M. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem., 1995, 270, 25752-61.
6. Yan, S.D.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; Slattery, T.; Zhao, L.; Nagashima, M.; Morser, J.; Migheli, A.; Nawroth, P.; Stern, D.; Schmidt, A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature, 1996, 382, 685-91
7. Chavakis, T.; Bierhaus, A.; Al-Fakhri, N.; Schneider, D.; Witte, S.; Linn, T.; Nagashima, M.; Morser, J.; Arnold, B.; Preissner, K.T.; Nawroth, P.P. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J. Exp. Med., 2003, 198, 1507-15.
8. Schmidt, A.M.; Yan, S.D.; Yan, S.F.; Stern, D.M. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta, 2000, 1498, 99-111.
9. Orlova, V.V.; Choi, E.Y.; Xie, C.; Chavakis, E.; Bierhaus, A.; Ihanus, E.; Ballantyne, C.M.; Gahmberg, C.G.; Bianchi, M.E.; Nawroth, P.P.; Chavakis, T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J., 2007, 26, 1129-39.
10. Schmidt, A.M.; Yan, S.D.; Wautier, J.L.; Stern, D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res., 1999, 84, 489-97.
11. Basta, G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis, 2008, 196, 9-21.
12. Tanji, N.; Markowitz, G.S.; Fu, C.; Kislinger, T.; Taguchi, A.; Pischetsrieder, M.; Stern, D.; Schmidt, A.M.; D'Agati, V.D. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol., 2000, 11, 1656-66.
13. Foell, D.; Kane, D.; Bresnihan, B.; Vogl, T.; Nacken, W.; Sorg, C.; Fitzgerald, O.; Roth, J. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford), 2003, 42, 1383-9.
14. Hofmann, M.A.; Drury, S.; Hudson, B.I.; Gleason, M.R.; Qu, W.; Lu, Y.; Lalla, E.; Chitnis, S.; Monteiro, J.; Stickland, M.H.; Bucciarelli, L.G.; Moser, B.; Moxley, G.; Itescu, S.; Grant, P.J.; Gregersen, P.K.; Stern, D.M.; Schmidt, A.M. RAGE and arthritis: The G82S polymorphism amplifies the inflammatory response. Genes Immun., 2002, 3, 123-35.
15. Schmidt, A.M.; Yan, S.D.; Yan, S.F.; Stern, D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest., 2001, 108, 949-55
16. Morbini, P.; Villa, C.; Campo, I.; Zorzetto, M.; Inghilleri, S.; Luisetti, M. The receptor for advanced glycation end products and its ligands: A new inflammatory pathway in lung disease? Mod. Pathol., 2006, 19, 1437-45.
17. Rong, L.L.; Gooch, C.; Szabolcs, M.; Herold, K.C.; Lalla, E.; Hays, A.P.; Yan, S.F.; Yan, S.S.; Schmidt, A.M. RAGE: A journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Restor Neurol. Neurosci., 2005, 23, 355-65.
18. Hermani, A.; De Servi, B.; Medunjanin, S.; Tessier, P.A.; Mayer, D. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp. Cell Res., 2006, 312, 184-97.
19. Taguchi, A.; Blood, D.C.; del Toro, G.; Canet, A.; Lee, D.C.; Qu, W.; Tanji, N.; Lu, Y.; Lalla, E.; Fu, C.; Hofmann, M.A.; Kislinger, T.; Ingram, M.; Lu, A.; Tanaka, H.; Hori, O.; Ogawa, S.; Stern, D.M.; Schmidt, A.M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature, 2000, 405, 354-60.
20. Ramasamy, R.; Vannucci, S.J.; Yan, S.S.; Herold, K.; Yan, S.F.; Schmidt, A.M. Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology, 2005, 15, 16R-28R.
21. Geroldi, D.; Falcone, C.; Minoretti, P.; Emanuele, E.; Arra, M.; D'Angelo, A. High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J. Am. Geriatr. Soc., 2006, 54, 1149-50.
22. Goldin, A.; Beckman, J.A.; Schmidt, A.M.; Creager, M.A. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation, 2006, 114, 597-605.
23. Kaneko, M.; Bucciarelli, L.; Hwang, Y.C.; Lee, L.; Yan, S.F.; Schmidt, A.M.; Ramasamy, R. Aldose reductase and AGE-RAGE pathways: Key players in myocardial ischemic injury. Ann. N. Y. Acad. Sci., 2005, 1043, 702-9.
24. Vincent, A.M.; Perrone, L.; Sullivan, K.A.; Backus, C.; Sastry, A.M.; Lastoskie, C.; Feldman, E.L. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology, 2007, 148, 548-58.
25. Wendt, T.; Tanji, N.; Guo, J.; Hudson, B.I.; Bierhaus, A.; Ramasamy, R.; Arnold, B.; Nawroth, P.P.; Yan, S.F.; D'Agati, V.; Schmidt, A.M. Glucose, glycation, and RAGE: Implications for amplification of cellular dysfunction in diabetic nephropathy. J. Am. Soc. Nephrol., 2003, 14, 1383-95.
26. Harja, E.; Bu, D.X.; Hudson, B.I.; Chang, J.S.; Shen, X.; Hallam, K.; Kalea, A.Z.; Lu, Y.; Rosario, R.H.; Oruganti, S.; Nikolla, Z.; Belov, D.; Lalla, E.; Ramasamy, R.; Yan, S.F.; Schmidt, A.M. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE mice. J. Clin. Invest., 2008, 118, 183-94.
27. Basta, G.; Lazzerini, G.; Del Turco, S.; Ratto, G.M.; Schmidt, A.M.; De Caterina, R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1401-7.
28. Krotz, F.; Sohn, H.Y.; Pohl, U. Reactive oxygen species: Players in the platelet game. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1988-96.
29. Shanmugam, N.; Kim, Y.S.; Lanting, L.; Natarajan, R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J. Biol. Chem., 2003, 278, 34834-44.
30. Barile, G.R.; Pachydaki, S.I.; Tari, S.R.; Lee, S.E.; Donmoyer, C.M.; Ma, W.; Rong, L.L.; Buciarelli, L.G.; Wendt, T.; Horig, H.; Hudson, B.I.; Qu, W.; Weinberg, A.D.; Yan, S.F.; Schmidt, A.M. The RAGE axis in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci., 2005, 46, 2916-24.
31. Haslbeck, K.M.; Neundorfer, B.; Schlotzer-Schrehardtt, U.; Bierhaus, A.; Schleicher, E.; Pauli, E.; Haslbeck, M.; Hecht, M.; Nawroth, P.; Heuss, D. Activation of the RAGE pathway: A general mechanism in the pathogenesis of polyneuropathies? Neurol. Res., 2007, 29, 103-10.
32. Bucciarelli, L.G.; Wendt, T.; Qu, W.; Lu, Y.; Lalla, E.; Rong, L.L.; Goova, M.T.; Moser, B.; Kislinger, T.; Lee, D.C.; Kashyap, Y.; Stern, D.M.; Schmidt, A.M. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation, 2002, 106, 2827-35.
33. Zhou, Z.; Wang, K.; Penn, M.S.; Marso, S.P.; Lauer, M.A.; Forudi, F.; Zhou, X.; Qu, W.; Lu, Y.; Stern, D.M.; Schmidt, A.M.; Lincoff, A.M.; Topol, E.J. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation, 2003, 107, 2238-43.
34. Sakaguchi, T.; Yan, S.F.; Yan, S.D.; Belov, D.; Rong, L.L.; Sousa, M.; Andrassy, M.; Marso, S.P.; Duda, S.; Arnold, B.; Liliensiek, B.; Nawroth, P.P.; Stern, D.M.; Schmidt, A.M.; Naka, Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J. Clin. Invest., 2003, 111, 959-72.
35. Bucciarelli, L.G.; Kaneko, M.; Ananthakrishnan, R.; Harja, E.; Lee, L.K.; Hwang, Y.C.; Lerner, S.; Bakr, S.; Li, Q.; Lu, Y.; Song, F.; Qu, W.; Gomez, T.; Zou, Y.S.; Yan, S.F.; Schmidt, A.M.; Ramasamy, R. Receptor for advanced-glycation end products: Key modulator of myocardial ischemic injury. Circulation, 2006, 113, 1226-34.
36. Wautier, J.L.; Zoukourian, C.; Chappey, O.; Wautier, M.P.; Guillausseau, P.J.; Cao, R.; Hori, O.; Stern, D.; Schmidt, A.M. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest., 1996, 97, 238-43.
37. Renard, C.; Chappey, O.; Wautier, M.P.; Nagashima, M.; Lundh, E.; Morser, J.; Zhao, L.; Schmidt, A.M.; Scherrmann, J.M.; Wautier, J.L. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharmacol., 1997, 52, 54-62.
38. Hanford, L.E.; Enghild, J.J.; Valnickova, Z.; Petersen, S.V.; Schaefer, L.M.; Schaefer, T.M.; Reinhart, T.A.; Oury, T.D. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem., 2004, 279, 50019-24.
39. Yonekura, H.; Yamamoto, Y.; Sakurai, S.; Petrova, R.G.; Abedin, M.J.; Li, H.; Yasui, K.; Takeuchi, M.; Makita, Z.; Takasawa, S.; Okamoto, H.; Watanabe, T.; Yamamoto, H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J., 2003, 370, 1097-109
40. Park, I.H.; Yeon, S.I.; Youn, J.H.; Choi, J.E.; Sasaki, N.; Choi, I.H.; Shin, J.S. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol. Immunol., 2004, 40, 1203-11.
41. Schlueter, C.; Hauke, S.; Flohr, A.M.; Rogalla, P.; Bullerdiek, J. Tissue-specific expression patterns of the RAGE receptor and its soluble forms - a result of regulated alternative splicing? Biochim. Biophys. Acta, 2003, 1630, 1-6.
42. Hudson, B.I.; Carter, A.M.; Harja, E.; Kalea, A.Z.; Arriero, M.; Yang, H.; Grant, P.J.; Schmidt, A.M. Identification, classification, and expression of RAGE gene splice variants. FASEB J., 2008, 22, 1572-80.
43. Harashima, A.; Yamamoto, Y.; Cheng, C.; Tsuneyama, K.; Myint, K.M.; Takeuchi, A.; Yoshimura, K.; Li, H.; Watanabe, T.; Takasawa, S.; Okamoto, H.; Yonekura, H.; Yamamoto, H. Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: Structure, function and expression. Biochem. J., 2006, 396, 109-15.
44. Raucci, A.; Cugusi, S.; Antonelli, A.; Barabino, S.M.; Monti, L.; Bierhaus, A.; Reiss, K.; Saftig, P.; Bianchi, M.E. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J., 2008, 22, 3716-27.
45. Cheng, C.; Tsuneyama, K.; Kominami, R.; Shinohara, H.; Sakurai, S.; Yonekura, H.; Watanabe, T.; Takano, Y.; Yamamoto, H.; Yamamoto, Y. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod. Pathol., 2005, 18, 1385-96.
46. Brett, J.; Schmidt, A.M.; Yan, S.D.; Zou, Y.S.; Weidman, E.; Pinsky, D.; Nowygrod, R.; Neeper, M.; Przysiecki, C.; Shaw, A.; Migheli, A.; Stern, D. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol., 1993, 143, 1699-712.
47. Yan, S.D.; Schmidt, A.M.; Anderson, G.M.; Zhang, J.; Brett, J.; Zou, Y.S.; Pinsky, D.; Stern, D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/ binding proteins. J. Biol. Chem., 1994, 269, 9889-97.
48. Tanaka, N.; Yonekura, H.; Yamagishi, S.; Fujimori, H.; Yamamoto, Y.; Yamamoto, H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem., 2000, 275, 25781-90.
49. Ritthaler, U.; Deng, Y.; Zhang, Y.; Greten, J.; Abel, M.; Sido, B.; Allenberg, J.; Otto, G.; Roth, H.; Bierhaus, A.; Ziegler, R.; Schmidt, A.M.; Waldherr, R.; Wahl, P.; Stern, D.; Nawroth, P. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am. J. Pathol., 1995, 146, 688- 4.
50. Burke, A.P.; Kolodgie, F.D.; Zieske, A.; Fowler, D.R.; Weber, D.K.; Varghese, P.J.; Farb, A.; Virmani, R. Morphologic findings of coronary atherosclerotic plaques in diabetics: A postmortem study. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1266-71.
51. Cipollone, F.; Iezzi, A.; Fazia, M.; Zucchelli, M.; Pini, B.; Cuccurullo, C.; De Cesare, D.; De Blasis, G.; Muraro, R.; Bei, R.; Chiarelli, F.; Schmidt, A.M.; Cuccurullo, F.; Mezzetti, A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation, 2003, 108, 1070-7.
52. Kunsch, C.; Medford, R.M. Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res., 1999, 85, 753-66.
53. De Kimpe, S.J.; Anggard, E.E.; Carrier, M.J. Reactive oxygen species regulate macrophage scavenger receptor type I, but not type II, in the human monocytic cell line THP-1. Mol. Pharmacol., 1998, 53, 1076-82.
54. Forbes, J.M.; Thorpe, S.R.; Thallas-Bonke, V.; Pete, J.; Thomas, M.C.; Deemer, E.R.; Bassal, S.; El-Osta, A.; Long, D.M.; Panagiotopoulos, S.; Jerums, G.; Osicka, T.M.; Cooper, M.E. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol., 2005, 16, 2363-72.
55. Yamagishi, S.; Imaizumi, T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler. Thromb. Vasc. Biol., 2007, 27, e32.
56. Nakamura, K.; Yamagishi, S.; Nakamura, Y.; Takenaka, K.; Matsui, T.; Jinnouchi, Y.; Imaizumi, T. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc. Res., 2005, 70, 137-41.
57. Pullerits, R.; Brisslert, M.; Jonsson, I.M.; Tarkowski, A. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum., 2006, 54, 3898-907.
58. Yamamoto, Y.; Miura, J.; Sakurai, S.; Watanabe, T.; Yonekura, H.; Tamei, H.; Matsuki, H.; Obata, K.-I.; Uchigata, Y.; Iwamoto, Y.; Koyama, H.; Yamamoto, H. Assaying Soluble Forms of Receptor for Advanced Glycation End Products. Arterioscler. Thromb. Vasc. Biol., 2007, 27, e33-4.
59. Humpert, P.M.; Djuric, Z.; Kopf, S.; Rudofsky, G.; Morcos, M.; Nawroth, P.P.; Bierhaus, A. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc. Diabetol., 2007, 6, 9.
60. Falcone, C.; Emanuele, E.; D'Angelo, A.; Buzzi, M.P.; Belvito, C.; Cuccia, M.; Geroldi, D. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1032-7.
61. Cuccurullo, C.; Iezzi, A.; Fazia, M.L.; De Cesare, D.; Di Francesco, A.; Muraro, R.; Bei, R.; Ucchino, S.; Spigonardo, F.; Chiarelli, F.; Schmidt, A.M.; Cuccurullo, F.; Mezzetti, A.; Cipollone, F. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2716-23.
62. Lindsey, J.B.; de Lemos, J.A.; Ayers, C.R.; Rohatgi, A.; Das, S.; Khera, A.; Morrow, D.A.; Cipollone, F.; McGuire, D.K. Soluble Receptor for Advanced Glycation End Products (sRAGE): A Novel Biomarker and Potential Inhibitor of Atherosclerosis. Observations From the Dallas Heart Study. J. Am. Coll. Cardiol., 2008, 51, A1007-205.
63. Catalano, M.; Cortelazzo, A.; Santi, R.; Contino, L.; Demicheli, M.; Yilmaz, Y.; Zorzetto, M.; Campo, I.; Lanati, N.; Emanuele, E. The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease. Clin. Biochem., 2008, 41, 981-5.
64. Hudson, B.I.; Harja, E.; Moser, B.; Schmidt, A.M. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: The next C-reactive protein? Arterioscler. Thromb. Vasc. Biol., 2005, 25, 879-82.
65. Emanuele, E.; D'Angelo, A.; Tomaino, C.; Binetti, G.; Ghidoni, R.; Politi, P.; Bernardi, L.; Maletta, R.; Bruni, A.C.; Geroldi, D. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol., 2005, 62, 1734-6.
66. Katakami, N.; Matsuhisa, M.; Kaneto, H.; Matsuoka, T.A.; Sakamoto, K.; Nakatani, Y.; Ohtoshi, K.; Hayaishi-Okano, R.; Kosugi, K.; Hori, M.; Yamasaki, Y. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: Its possible association with diabetic vascular complications. Diabetes Care, 2005, 28, 2716-21.
67. Koyama, H.; Shoji, T.; Yokoyama, H.; Motoyama, K.; Mori, K.; Fukumoto, S.; Emoto, M.; Tamei, H.; Matsuki, H.; Sakurai, S.; Yamamoto, Y.; Yonekura, H.; Watanabe, T.; Yamamoto, H.; Nishizawa, Y. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 2587-93.
68. Choi, K.M.; Yoo, H.J.; Kim, H.Y.; Lee, K.W.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Choi, D.S.; Baik, S.H. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int. J. Cardiol., 2008 Jan 9. [Epub ahead of print].
69. Basta, G.; Sironi, A.M.; Lazzerini, G.; Del Turco, S.; Buzzigoli, E.; Casolaro, A.; Natali, A.; Ferrannini, E.; Gastaldelli, A. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J. Clin. Endocrinol. Metab., 2006, 91, 4628-34.
70. Ceriello, A.; Motz, E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 816-23.
71. Davi, G.; Ciabattoni, G.; Consoli, A.; Mezzetti, A.; Falco, A.; Santarone, S.; Pennese, E.; Vitacolonna, E.; Bucciarelli, T.; Costantini, F.; Capani, F.; Patrono, C. In vivo formation of 8-isoprostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation, 1999, 99, 224-9.
72. Santilli, F.; Davi, G.; Consoli, A.; Cipollone, F.; Mezzetti, A.; Falco, A.; Taraborelli, T.; Devangelio, E.; Ciabattoni, G.; Basili, S.; Patrono, C. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J. Am. Coll. Cardiol., 2006, 47, 391-7
73. Davi, G.; Falco, A.; Patrono, C. Lipid peroxidation in diabetes mellitus. Antioxid. Redox. Signal., 2005, 7, 256-68.
74. Davi, G.; Falco, A.; Patrono, C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem. Phys. Lipids, 2004, 128, 149-63.
75. Devangelio, E.; Santilli, F.; Formoso, G.; Ferroni, P.; Bucciarelli, L.; Michetti, N.; Clissa, C.; Ciabattoni, G.; Consoli, A.; Davi, G. Soluble RAGE in type 2 diabetes: Association with oxidative stress. Free Radic. Biol. Med., 2007, 43, 511-8.
76. Lin, K.Y.; Ito, A.; Asagami, T.; Tsao, P.S.; Adimoolam, S.; Kimoto, M.; Tsuji, H.; Reaven, G.M.; Cooke, J.P. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation, 2002, 106, 987-92.
77. Yamagishi, S.; Ueda, S.; Okuda, S. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes. Med. Hypotheses, 2007, 69, 922-4.
78. Yin, Q.F.; Fu, S.H.; He, P.; Xiong, Y. Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: Effects of aminoguanidine. Atherosclerosis, 2007, 190, 53-61.
79. Unoki, H.; Bujo, H.; Yamagishi, S.; Takeuchi, M.; Imaizumi, T.; Saito, Y. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res. Clin. Pract., 2007, 76, 236-44.
80. Davi, G.; Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med., 2007, 357, 2482-94.
81. Ferroni, P.; Santilli, F.; Guadagni, F.; Basili, S.; Davi, G. Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. Curr. Med. Chem., 2007, 14, 2170-80.
82. Vasan, R.S. Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation, 2006, 113, 2335-62.
83. Verzijl, N.; DeGroot, J.; Thorpe, S.R.; Bank, R.A.; Shaw, J.N.; Lyons, T.J.; Bijlsma, J.W.; Lafeber, F.P.; Baynes, J.W.; TeKoppele, J.M. Effect of collagen turnover on the accumulation of advanced glycation end products. J. Biol. Chem., 2000, 275, 39027-31.
84. Humpert, P.M.; Kopf, S.; Djuric, Z.; Wendt, T.; Morcos, M.; Nawroth, P.P.; Bierhaus, A. Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care, 2006, 29, 1111-3.
85. Tan, K.C.; Shiu, S.W.; Chow, W.S.; Leng, L.; Bucala, R.; Betteridge, D.J. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia, 2006, 49, 2756-62.
86. Koyama, H.; Yamamoto, H.; Nishizawa, Y. RAGE and soluble RAGE: Potential therapeutic targets for cardiovascular diseases. Mol. Med., 2007, 13, 625-35.
87. Ebihara, I.; Nakamura, T.; Shimada, N.; Koide, H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am. J. Kidney Dis., 1998, 32, 544-50.
88. Lovell, H.G. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Syst. Rev., 2001, CD002183.
89. Koyama, H.; Shoji, T.; Fukumoto, S.; Shinohara, K.; Emoto, M.; Mori, K.; Tahara, H.; Ishimura, E.; Kakiya, R.; Tabata, T.; Yamamoto, H.; Nishizawa, Y. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 147-53.
90. Schiffrin, E.L.; Lipman, M.L.; Mann, J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation, 2007, 116, 85-97.
91. Kalousova, M.; Hodkova, M.; Kazderova, M.; Fialova, J.; Tesar, V.; Dusilova-Sulkova, S.; Zima, T. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am. J. Kidney Dis., 2006, 47, 406-11.
92. Pullerits, R.; Bokarewa, M.; Dahlberg, L.; Tarkowski, A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res. Ther., 2005, 7, R817-24.
93. Moser, B.; Hudson, B.I.; Schmidt, A.M. Soluble RAGE: A hot new biomarker for the hot joint? Arthritis Res. Ther., 2005, 7, 142-4.
94. Tan, K.C.; Chow, W.S.; Tso, A.W.; Xu, A.; Tse, H.F.; Hoo, R.L.; Betteridge, D.J.; Lam, K.S. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia, 2007, 50, 1819-25.
95. Wang, K.; Zhou, Z.; Zhang, M.; Fan, L.; Forudi, F.; Zhou, X.; Qu, W.; Lincoff, A.M.; Schmidt, A.M.; Topol, E.J.; Penn, M.S. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J. Pharmacol. Exp. Ther., 2006, 317, 37-43
96. Santilli, F.; Bucciarelli, L.; Noto, D.; Cefalu, A.B.; Davi, V.; Ferrante, E.; Pettinella, C.; Averna, M.R.; Ciabattoni, G.; Davi, G. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med., 2007, 43, 1255-62.
97. Emanuele, E.; Geroldi, D. A novel mechanism of action of atorvastatin against cardiovascular risk: A commentary on "decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins". Free Radic. Biol. Med., 2007, 43, 1231-2.
98. Yamagishi, S.; Nakamura, K.; Matsui, T.; Inoue, H. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders. Med. Hypotheses, 2007, 69, 338-40.
99. Jinnouchi, Y.; Yamagishi, S.; Takeuchi, M.; Ishida, S.; Jinnouchi, J.; Imaizumi, T. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin. Exp. Med., 2006, 6, 191-3.
100. Ridker, P.M.; Cannon, C.P.; Morrow, D.; Rifai, N.; Rose, L.M.; McCabe, C.H.; Pfeffer, M.A.; Braunwald, E. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med., 2005, 352, 20-8.
101. Sugaya, K.; Fukagawa, T.; Matsumoto, K.; Mita, K.; Takahashi, E.; Ando, A.; Inoko, H.; Ikemura, T. Three genes in the human MHC class III region near the junction with the class II: Gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics, 1994, 23, 408-19.
102. Hudson, B.I.; Stickland, M.H.; Futers, T.S.; Grant, P.J. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes, 2001, 50, 1505-11.
103. Hudson, B.I.; Stickland, M.H.; Grant, P.J. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: Prevalence in type 2 diabetes and ethnic groups. Diabetes, 1998, 47, 1155-7.
104. Pettersson-Fernholm, K.; Forsblom, C.; Hudson, B.I.; Perola, M.; Grant, P.J.; Groop, P.H. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes, 2003, 52, 891-4.
105. Lindholm, E.; Bakhtadze, E.; Sjogren, M.; Cilio, C.M.; Agardh, E.; Groop, L.; Agardh, C.D. The -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. Diabetologia, 2006, 49, 2745-55.
106. Falcone, C.; Campo, I.; Emanuele, E.; Buzzi, M.P.; Zorzetto, M.; Sbarsi, I.; Cuccia, M. Relationship between the -374T/A RAGE gene polymorphism and angiographic coronary artery disease. Int. J. Mol. Med., 2004, 14, 1061-4.
107. Sullivan, C.M.; Futers, T.S.; Barrett, J.H.; Hudson, B.I.; Freeman, M.S.; Grant, P.J. RAGE polymorphisms and the heritability of insulin resistance: The Leeds family study. Diab. Vasc. Dis. Res., 2005, 2, 42-4.
108. Hofmann, M.A.; Yang, Q.; Harja, E.; Kedia, P.; Gregersen, P.K.; Cupples, L.A.; Schmidt, A.M.; Hudson, B.I. The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham offspring study. Atherosclerosis, 2005, 182, 301-5.
109. Carroll, L.; Frazer, I.H.; Turner, M.; Marwick, T.H.; Thomas, R. Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis. Arthritis Res. Ther., 2007, 9, R39.
110. Prevost, G.; Fajardy, I.; Besmond, C.; Balkau, B.; Tichet, J.; Fontaine, P.; Danze, P.M.; Marre, M. Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab., 2005, 31, 35-9.
111. Gaens, K.; van der Kallen, C.; van Greevenbroek, M.; Feskens, E.; Stehouwer, C.; Schalkwijk, C. Receptor for Advanced Glycation End Product Polymorphisms and Type 2 Diabetes: The CODAM Study. Ann. N. Y. Acad. Sci., 2008, 1126, 162-5.
112. Jang, Y.; Kim, J.Y.; Kang, S.M.; Kim, J.S.; Chae, J.S.; Kim, O.Y.; Koh, S.J.; Lee, H.C.; Ahn, C.W.; Song, Y.D.; Lee, J.H. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism, 2007, 56, 199-205.
113. Yamagishi, S.; Adachi, H.; Nakamura, K.; Matsui, T.; Jinnouchi, Y.; Takenaka, K.; Takeuchi, M.; Enomoto, M.; Furuki, K.; Hino, A.; Shigeto, Y.; Imaizumi, T. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism., 2006, 55, 1227-31.
114. Nakamura, K.; Yamagishi, S.; Adachi, H.; Kurita-Nakamura, Y.; Matsui, T.; Yoshida, T.; Sato, A.; Imaizumi, T. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab. Res. Rev., 2007, 23, 368-71.
115. Nakamura, K.; Yamagishi, S.I.; Adachi, H.; Matsui, T.; Kurita-Nakamura, Y.; Takeuchi, M.; Inoue, H.; Imaizumi, T. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab. Res. Rev., 2008, 24, 109-14.
116. Nakamura, K.; Yamagishi, S.; Adachi, H.; Kurita-Nakamura, Y.; Matsui, T.; Yoshida, T.; Imaizumi, T. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol. Med., 2007, 13, 185-9.
117. Ridker, P.M.; Brown, N.J.; Vaughan, D.E.; Harrison, D.G.; Mehta, J.L. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation, 2004, 109, IV6-19.
118. Packard, R.R.; Libby, P. Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction. Clin. Chem., 2008, 54, 24-38.
119. Chan, A.O.; Jim, M.H.; Lam, K.F.; Morris, J.S.; Siu, D.C.; Tong, T.; Ng, F.H.; Wong, S.Y.; Hui, W.M.; Chan, C.K.; Lai, K.C.; Cheung, T.K.; Chan, P.; Wong, G.; Yuen, M.F.; Lau, Y.K.; Lee, S.; Szeto, M.L.; Wong, B.C.; Lam, S.K. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA, 2007, 298, 1412-9.